These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 31254921)

  • 21. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.
    Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors.
    Hassan GS; Georgey HH; Mohammed EZ; George RF; Mahmoud WR; Omar FA
    Eur J Med Chem; 2021 Jun; 218():113389. PubMed ID: 33784602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis, Docking Studies into CDK-2 and Anticancer Activity of New Derivatives Based Pyrimidine Scaffold and Their Derived Glycosides.
    Rahman AAHA; Nassar IF; Shaban AKF; El-Kady DS; Awad HM; El Sayed WA
    Mini Rev Med Chem; 2019; 19(13):1093-1110. PubMed ID: 30864522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
    Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
    Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, anticancer evaluation and molecular docking of new benzothiazole scaffolds targeting FGFR-1.
    Abd El-Meguid EA; Mohi El-Deen EM; Moustafa GO; Awad HM; Nossier ES
    Bioorg Chem; 2022 Feb; 119():105504. PubMed ID: 34836644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors.
    Cherukupalli S; Chandrasekaran B; Kryštof V; Aleti RR; Sayyad N; Merugu SR; Kushwaha ND; Karpoormath R
    Bioorg Chem; 2018 Sep; 79():46-59. PubMed ID: 29753773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of newly synthesised quinazolinone-based CDK2 inhibitors with potent efficacy against melanoma.
    Mohammed ER; Elmasry GF
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):686-700. PubMed ID: 35139719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.
    Lin T; Li J; Liu L; Li Y; Jiang H; Chen K; Xu P; Luo C; Zhou B
    Eur J Med Chem; 2021 Apr; 215():113281. PubMed ID: 33611192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
    Nan X; Li HJ; Fang SB; Li QY; Wu YC
    Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
    Elgazwy AS; Ismail NS; Elzahabi HS
    Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, biological evaluation, and molecular docking studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline derivatives as novel anticancer agents.
    Huang XF; Lu X; Zhang Y; Song GQ; He QL; Li QS; Yang XH; Wei Y; Zhu HL
    Bioorg Med Chem; 2012 Aug; 20(16):4895-900. PubMed ID: 22819191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
    Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
    Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea/thiourea moieties with potential cytotoxicity and CDK inhibitory activities.
    Shawky AM; Ibrahim NA; Abourehab MAS; Abdalla AN; Gouda AM
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):15-33. PubMed ID: 33103497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis, anticancer activity and docking of some substituted benzothiazoles as tyrosine kinase inhibitors.
    Bhuva HA; Kini SG
    J Mol Graph Model; 2010 Aug; 29(1):32-7. PubMed ID: 20493747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
    Zhao P; Li Y; Gao G; Wang S; Yan Y; Zhan X; Liu Z; Mao Z; Chen S; Wang L
    Eur J Med Chem; 2014 Oct; 86():165-74. PubMed ID: 25151579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.
    Park SJ; Kim E; Yoo M; Lee JY; Park CH; Hwang JY; Ha JD
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4399-4404. PubMed ID: 28827110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers.
    Roy T; Boateng ST; Banang-Mbeumi S; Singh PK; Basnet P; Chamcheu RN; Ladu F; Chauvin I; Spiegelman VS; Hill RA; Kousoulas KG; Nagalo BM; Walker AL; Fotie J; Murru S; Sechi M; Chamcheu JC
    Bioorg Chem; 2021 Feb; 107():104595. PubMed ID: 33450548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
    Wang R; Chen Y; Zhao X; Yu S; Yang B; Wu T; Guo J; Hao C; Zhao D; Cheng M
    Eur J Med Chem; 2019 Dec; 183():111716. PubMed ID: 31550660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.
    Řezníčková E; Weitensteiner S; Havlíček L; Jorda R; Gucký T; Berka K; Bazgier V; Zahler S; Kryštof V; Strnad M
    Chem Biol Drug Des; 2015 Dec; 86(6):1528-40. PubMed ID: 26198005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.